BioTelemetry, CardioNet To Pay $44.8M To Settle FCA Case
Medical device manufacturer BioTelemetry and its subsidiary CardioNet have agreed to pay $44.8 million to resolve whistleblower claims accusing them of submitting fraudulent claims to federal health care programs for heart...To view the full article, register now.
Already a subscriber? Click here to view full article